tetano
Editor, Senior Moderator
Diabetol Int
. 2024 Feb 29;15(3):577-582.
doi: 10.1007/s13340-024-00695-9. eCollection 2024 Jul. Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature
Shota Mochizuki[SUP] 1 [/SUP], Junnosuke Miura[SUP] 1 [/SUP], Kiwako Ucida[SUP] 1 [/SUP], Ryo Kubota[SUP] 1 [/SUP], Hirona Fujikawa[SUP] 1 [/SUP], Satoshi Takagi[SUP] 1 [/SUP], Naoshi Yoshida[SUP] 1 [/SUP], Sachiko Ootake[SUP] 1 2 [/SUP], Chika Fujimori[SUP] 3 [/SUP], Akihito Shinohara[SUP] 3 [/SUP], Junji Tanaka[SUP] 3 [/SUP], Tetsuya Babazono[SUP] 1 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection, which led to the coronavirus 2019 (COVID-19) pandemic, has promoted the development of novel therapeutic agents and vaccines to combat the global spread of the virus. While the COVID-19 vaccines approved thus far have proven to be effective in clinical settings, there have been reports of autoimmune diseases occurring following vaccination, including autoimmune/inflammatory syndrome induced by adjuvant syndrome. We herein report two cases of type 1 diabetes mellitus that occurred following COVID-19 vaccination and provide a literature review. Both cases received multiple vaccinations as recommended to ensure optimal antibody titers. Moreover, the HLA associated with susceptibility to type 1 diabetes was prototypic in both cases. This indirect evidence suggests that the COVID-19 vaccines may be implicated in the pathogenesis of type 1 diabetes. Further case reports to establish a clearer understanding of a potential association are warranted.
Supplementary information: The online version contains supplementary material available at 10.1007/s13340-024-00695-9.
Keywords: COVID-19 vaccine; Islet-associated autoantibodies; Type 1 diabetes; Vaccine side effects.
. 2024 Feb 29;15(3):577-582.
doi: 10.1007/s13340-024-00695-9. eCollection 2024 Jul. Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature
Shota Mochizuki[SUP] 1 [/SUP], Junnosuke Miura[SUP] 1 [/SUP], Kiwako Ucida[SUP] 1 [/SUP], Ryo Kubota[SUP] 1 [/SUP], Hirona Fujikawa[SUP] 1 [/SUP], Satoshi Takagi[SUP] 1 [/SUP], Naoshi Yoshida[SUP] 1 [/SUP], Sachiko Ootake[SUP] 1 2 [/SUP], Chika Fujimori[SUP] 3 [/SUP], Akihito Shinohara[SUP] 3 [/SUP], Junji Tanaka[SUP] 3 [/SUP], Tetsuya Babazono[SUP] 1 [/SUP]
Affiliations
- PMID: 39101197
- PMCID: PMC11291814 (available on 2025-02-28)
- DOI: 10.1007/s13340-024-00695-9
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection, which led to the coronavirus 2019 (COVID-19) pandemic, has promoted the development of novel therapeutic agents and vaccines to combat the global spread of the virus. While the COVID-19 vaccines approved thus far have proven to be effective in clinical settings, there have been reports of autoimmune diseases occurring following vaccination, including autoimmune/inflammatory syndrome induced by adjuvant syndrome. We herein report two cases of type 1 diabetes mellitus that occurred following COVID-19 vaccination and provide a literature review. Both cases received multiple vaccinations as recommended to ensure optimal antibody titers. Moreover, the HLA associated with susceptibility to type 1 diabetes was prototypic in both cases. This indirect evidence suggests that the COVID-19 vaccines may be implicated in the pathogenesis of type 1 diabetes. Further case reports to establish a clearer understanding of a potential association are warranted.
Supplementary information: The online version contains supplementary material available at 10.1007/s13340-024-00695-9.
Keywords: COVID-19 vaccine; Islet-associated autoantibodies; Type 1 diabetes; Vaccine side effects.